AI Article Synopsis
- Previous research suggests that environmental factors may account for 70% to 90% of cancer cases, highlighting the significance of these extrinsic elements in cancer development.
- Many cancer patients and survivors tend to remain in the same neighborhoods where they lived before their diagnosis, which means they continue to be exposed to potential carcinogens.
- This commentary reviews existing studies linking particulate matter (PM) with cancer mortality and post-treatment health issues, and it calls for more research to explore these important connections.
Article Abstract
Previous studies of the environment and cancer have focused on etiology, showing that extrinsic factors in the environment contribute to 70% to 90% of cancers. Cancer patients and survivors often continue to live in the same neighborhoods they resided in before their cancer diagnosis. Thus, patients and survivors are exposed to the same environmental contexts that likely contributed to their original cancer, but little is known about the health effects of continued exposure to carcinogens after a cancer diagnosis. This commentary provides a summary of studies of the association between PM and cancer mortality among patients and PM and posttreatment morbidity among cancer survivors, and proposes new directions and opportunities for future research on such topics.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170704 | PMC |
| http://dx.doi.org/10.1158/1055-9965.EPI-19-1588 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of 8-(2-methyl phenyl)-9H-benzo[f]indeno[2,1-c]quinolin-9-one (C-5635020) as a novel and selective TGFβ RII kinase inhibitor for breast cancer therapy.
Biochem Biophys Res Commun
January 2025
Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia. Electronic address:
Objective And Significance: Transforming growth factor-beta (TGF-β) plays a pivotal role in breast development by modulating tissue composition during the developmental phase. The TGFβ type II receptor (TGFβ RII) is implicated in breast cancer and represents a valuable therapeutic target. Due to the off-target side effects of many existing TGFβI/TGFβ RII inhibitors, a more targeted approach to drug discovery is necessary.
View Article and Find Full Text PDFKnowledge domain and frontier trends of artificial intelligence applied in solid organ transplantation: A visualization analysis.
Int J Med Inform
December 2024
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. Electronic address:
Background: Solid organ transplantation (SOT) is vital for end-stage organ failure but faces challenges like organ shortage and rejection. Artificial intelligence (AI) offers potential to improve outcomes through better matching, success prediction, and automation. However, the evolution of AI in SOT research remains underexplored.
View Article and Find Full Text PDFExploring 1,2,3-triazole-Schiff's base hybrids as innovative EGFR inhibitors for the treatment of breast cancer: In vitro and in silico study.
Bioorg Chem
January 2025
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt. Electronic address:
EGFR inhibitors are a class of targeted therapies utilized in the management of certain tumor kinds such as NSCLC and breast cancer. Series of 1,2,3-triazole-Schiff's base hybrids were designed, synthesized, and estimated for their antitumor effect toward breast cancer cells, MCF-7 and MDA-MB-231. The safety and selectivity of the new compounds were tested using normal cell (WI-38).
View Article and Find Full Text PDFData Resource Profile: Harmonized health survey data for 240 cities across 11 countries in Latin America: the SALURBAL project.
Int J Epidemiol
December 2024
Urban Health Collaborative, Dornsife School of Public Health, Drexel University, Philadelphia, PA, USA.
Assessing the Risk for Falls in Older Adults After Initiating Gabapentin Versus Duloxetine.
Ann Intern Med
January 2025
Center for Healthcare Delivery Sciences, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (R.J.D., N.K.C., N.H., J.C.L.).
Background: The evidence informing the harms of gabapentin use are at risk of bias from comparing users with nonusers.
Objective: To describe the risk for fall-related outcomes in older adults starting treatment with gabapentin versus duloxetine.
Design: New user, active comparator study using a target trial emulation framework.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!